This study is testing the effects on weight loss of a capsule-delivered device that expands in the stomach to help create a sense of fullness. The device then leaves the stomach, disintegrates and is excreted. In this study participants will receive either the device or a placebo capsule that looks the same. Participants will receive dietary and exercise counseling at most visits to help them lose weight. The 24-week losses of participants who get the device will be compared to the losses of those who get the placebo capsule to determine the effect on weight loss. Changes in other health markers will also be assessed.
TARGET-HCC is a 5-year, longitudinal, observational study of the natural history and management of patients with HCC. The study will address important clinical questions that remain unanswered in the management of HCC with a unique research registry of participants with HCC from academic and community real-world practices. TARGET-HCC is disease focused, not drug specific, which allows for continuous acquisition of real-world evidence regarding the natural history, management, and outcomes of treatment with current therapies and new treatments that may be utilized in usual clinical practice.
This is a 5-year, longitudinal, observational study of patients with NAFL or NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.